Source link : https://www.newshealth.biz/health-news/ada-advises-against-using-compounded-glp-1-ra-medications/
In a new statement, the American Diabetes Association (ADA) has advised against the use of compounded glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA medication classes. The ADA recommends GLP-1 RA and GIP/GLP-1 RA medications approved by the US Food and Drug Administration (FDA) for the treatment of type […]
Author : News Health
Publish date : 2024-12-03 06:45:12
Copyright for syndicated content belongs to the linked Source.